Novartis AG ADR (NYSE: NVS) has a price-to-earnings ratio of 18.52x that is above its average ratio. Additionally, the 36-month beta value for NVS is 0.55. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 10 rating it as “hold,” and 2 rating it as “sell.”
The public float for NVS is 1.98B and currently, short sellers hold a 0.25% ratio of that float. The average trading volume of NVS on March 12, 2025 was 1.83M shares.
NVS) stock’s latest price update
Novartis AG ADR (NYSE: NVS)’s stock price has dropped by -2.29 in relation to previous closing price of 111.35. Nevertheless, the company has seen a loss of -2.75% in its stock price over the last five trading days. zacks.com reported 2025-03-07 that If the cancer space appeals to you, it’s time to consider stocks like Novartis, Exact Sciences and Monte Rosa.
NVS’s Market Performance
Novartis AG ADR (NVS) has experienced a -2.75% fall in stock performance for the past week, with a 1.82% rise in the past month, and a 6.68% rise in the past quarter. The volatility ratio for the week is 1.48%, and the volatility levels for the past 30 days are at 1.36% for NVS. The simple moving average for the past 20 days is -0.78% for NVS’s stock, with a 0.56% simple moving average for the past 200 days.
NVS Trading at 3.93% from the 50-Day Moving Average
After a stumble in the market that brought NVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.02% of loss for the given period.
Volatility was left at 1.36%, however, over the last 30 days, the volatility rate increased by 1.48%, as shares surge +0.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.39% upper at present.
During the last 5 trading sessions, NVS fell by -2.91%, which changed the moving average for the period of 200-days by +6.53% in comparison to the 20-day moving average, which settled at $109.65. In addition, Novartis AG ADR saw 11.81% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVS starting from Kowalski Robert William, who proposed sale 6,566 shares at the price of $111.72 back on Aug 12 ’24. After this action, Kowalski Robert William now owns shares of Novartis AG ADR, valued at $733,572 using the latest closing price.
Stock Fundamentals for NVS
Current profitability levels for the company are sitting at:
- 0.28 for the present operating margin
- 0.75 for the gross margin
The net margin for Novartis AG ADR stands at 0.23. The total capital return value is set at 0.2. Equity return is now at value 26.33, with 11.34 for asset returns.
Based on Novartis AG ADR (NVS), the company’s capital structure generated 0.42 points at debt to capital in total, while cash flow to debt ratio is standing at 0.56. The debt to equity ratio resting at 0.71. The interest coverage ratio of the stock is 14.46.
Currently, EBITDA for the company is 20.71 billion with net debt to EBITDA at 0.96. When we switch over and look at the enterprise to sales, we see a ratio of 4.54. The receivables turnover for the company is 5.42for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.04.
Conclusion
In conclusion, Novartis AG ADR (NVS) has seen better performance in recent times. Analysts have a bearish opinion on the stock, with some rating it as a “sell” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
